BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/14/2025 10:33:40 AM | Browse: 215 | Download: 954
 |
Received |
|
2024-10-08 07:42 |
|
Peer-Review Started |
|
2024-10-08 07:42 |
|
First Decision by Editorial Office Director |
|
2024-12-05 09:41 |
|
Return for Revision |
|
2024-12-05 09:41 |
|
Revised |
|
2024-12-16 12:10 |
|
Publication Fee Transferred |
|
2024-12-19 08:42 |
|
Second Decision by Editor |
|
2025-01-08 02:37 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-01-08 07:30 |
|
Articles in Press |
|
2025-01-08 07:30 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-01-22 04:17 |
|
Publish the Manuscript Online |
|
2025-02-14 10:33 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
IL-22/IL-22R1 pathway enhances cholangiocarcinoma progression via ERK1/2 activation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jin Zhou, Jing-Rui Chen, Jin-Ming Li, Shuang-Qing Han, Xi-Yue Deng, Zhong-Min Li, Wen Tong, Chao Wang, Yi Bai and Ya-Min Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82372194 |
|
| Corresponding Author |
Ya-Min Zhang, Chief Physician, PhD, Department of Hepatobiliary Surgery, Tianjin First Central Hospital, No. 24 Fukang Road, Nankai District, Tianjin 300070, China. zhangyamin@nankai.edu.cn |
| Key Words |
Cholangiocarcinoma; IL-22; IL-22R1; ERK1/2; Cancer progression |
| Core Tip |
This research results show that IL-22R1 is highly expressed in cholangiocarcinoma (CCA) cell lines and tissues. The binding of IL-22 to IL-22R1 forms the IL-22/IL-22R1 axis, which can promote the progression of CCA both in vivo and in vitro. The application of ERK1/2 inhibitors can reverse the promoting effect of IL-22 on CCA, providing potential therapeutic strategies for CCA’s clinical treatment. |
| Publish Date |
2025-02-14 10:33 |
| Citation |
Zhou J, Chen JR, Li JM, Han SQ, Deng XY, Li ZM, Tong W, Wang C, Bai Y, Zhang YM. IL-22/IL-22R1 pathway enhances cholangiocarcinoma progression via ERK1/2 activation. World J Gastrointest Oncol 2025; 17(3): 102083 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i3/102083.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i3.102083 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
